Efficacy, Safety, and Tolerability of Efgartigimod in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Results from the ADHERE Trial (PL5.002)

Jeffrey A. Allen; Ivana Basta; Christian Eggers; Jeffrey T. Guptill; Kelly Gwathmey; Channa Hewamadduma; Erik Hofman; Yessar Hussain; Satoshi Kuwabara; Frank Leypoldt; Jie Lin; Marta Lipowska; Murray Lowe; Giuseppe Lauria; Luís Querol; Niraja Suresh; Anissa Tse; Peter Ulrichts; P. van Doorn; Benjamin Van Hoorick; Ryo Yamasaki; Richard A. Lewis

doi:10.1212/wnl-.0000000000206324

Abstract

Assess the efficacy and safety of subcutaneous (SC) efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in chronic inflammatory demyelinating polyneuropathy (CIDP).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Allen et al. (2024) studied this question.

synapsesocial.com/papers/68e6fca8b6db64358767694c https://doi.org/10.1212/wnl-.0000000000206324

View Full Paper

Ask AI

Bookmark

Abstract

Assess the efficacy and safety of subcutaneous (SC) efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in chronic inflammatory demyelinating polyneuropathy (CIDP).

Efficacy, Safety, and Tolerability of Efgartigimod in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Results from the ADHERE Trial (PL5.002)

Abstract

Discussion

Cite This Study

Efficacy, Safety, and Tolerability of Efgartigimod in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Results from the ADHERE Trial (PL5.002)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading